HNN3.0

Department of Pharmaceutical Sciences, University of Latvia

University

www.lu.lv/en/about-us/about-ul/Riga, Latvia
1 profile visit

About

Department Pharmaceutical Sciences at the Faculty of Medicine and Life Sciences, University of Latvia, provide a full set of experimental testing from two-dimensional (2D) and three-dimensional (3D) cell culture models, including patient-derived organoids, pancreatic, kidney and liver organ-on-chip microfluidics systems, and induced pluripotent stem cell (iPSC) technologies, to in vivo zebrafish model, followed by tissue analysis, evaluation of genetic and epigenetic biomarkers by utilizing machine learning models to predict the progression of disease and therapy efficacy, analyzing cell interaction in tumor microenvironment and assessing compound toxicity.

Representatives

full professor

Department of Pharmaceutical Sciences, University of Latvia

Lead researcher

Department of Pharmaceutical Sciences, University of Latvia

Marketplace (3)

  • Project cooperation

    New Approach Methodologies: patient-derived iPSC models

    Rare disease patient-derived iPSC models for personalized therapy development

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    Author

    full professor at Department of Pharmaceutical Sciences, University of Latvia

    Riga, Latvia

  • Project cooperation

    Patient-Derived Zebrafish Larvae Xenografts for Drug Efficacy and Stroma-Interaction Studies

    Our zebrafish avatar NAM offers 3R-compliant, real-time efficacy and toxicity profiling of patient-derived grafts in transgenic fish.

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    Author

    Lead researcher at Department of Pharmaceutical Sciences, University of Latvia

    Riga, Latvia

  • Project cooperation

    NAM: organoids and OoC for drug discovery, and precision medicine applications

    We have expertise on organoids derived from primary tumour tissues and matched normal counterparts, and OoC development.

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    Author

    full professor at Department of Pharmaceutical Sciences, University of Latvia

    Riga, Latvia